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Background: Persistent infection of human papillomavirus (HPV) types 16 and 18 causes cervical cancer. To better
understand immune responses to the prophylactic vaccine, HPV 16/18 L1 virus-like particles (HPV-VLPs), we
investigated B cell epitopes of HPV16 L1-derived peptides.
Methods: Sera from mice immunized with HPV-16/18 L1 VLPs were analyzed for their IgG titers against 10 different
HPV16 L1-derived peptides (20-mer) that contain human leukocyte antigen (HLA)-class I A-2, A-24 and class II DR.
Results: One 20-mer peptide at positions 300 to 319 was identified as a common B cell epitope in both Balb/c (H-
2d) and C57BL/6 (H-2b) mice. Mapping analysis showed that the 10-amino-acid sequence at positions 304to 313
was an immunogenic portion. It is of note that the binding capability of this 10-mer peptide to the HLA-A2 and
HLA-A24 molecules was confirmed by the HLA class I stabilization assay. In addition, one unique 20-mer was
determined as a B cell epitope in each strain.
Conclusions: These results might provide new information for better understanding of immune responses to HPV
16 L1.
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Cervical cancer is the second most prevalent cancer in
women worldwide. HPV 16 is the most common type
associated with cervical cancer [1]. HPV-16/18L1 virus-
like particles (HPV-VLPs), which induce neutralizing
antibody responses, have been used as a prophylactic
vaccine with great success [2,3]. Although the preventive
effect of the HPV-VLPs vaccine has been reported to last
up to 7.3 years [4], the durability is unclear at the
present time, either for the entire vaccinated population
or for individuals. This hurdle could be in part overcome
if predictable biomarkers were identified. One of the bio-
markers could be based on the measurement of specific
humoral immune responses to the vaccine. However, lit-
tle information is presently available with regard to
humoral responses against the HPV-VLPs, primarily* Correspondence: kawano_kouichirou@kurume-u.ac.jp
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reproduction in any medium, provided the orbecause of the limited availability of the assay reagents
[5,6]. The main aim of this study was to better under-
stand humoral immune responses to HPV16 L1-derived
peptides in an animal model.Results
Detection of IgG antibodies in serum of Balb/c mice
Serum of the Balb/c mice was obtained before
immunization, and 3, 5, 8, 11, 14 weeks after the first
immunization. Each group consisted of 6 mice, and
serum from each mouse was independently measured
for IgG level. A 100-fold dilution of samples was used to
determine the levels of IgG reactive to each of 10 differ-
ent HPV16 L1-derived peptides (20-mer), and the results
were given in fluorescent intensity units (FIU) (Figure 1).
Representative results of a kinetic study showed that IgG
against peptide 4 and peptide 6, but not any others, be-
came detectable at 3 weeks and reached a maximum at
5 weeks (P<0.05) followed by decline thereafter until
11 weeks. IgG levels were somewhat increased again at
14 weeks, which might be in part a reflection of thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and



































Figure 1 The kinetics of antibody production in Balb/c mice.
Serum (100-fold dilution) of each of 6 Balb/c mice was obtained
before immunization, and 3, 5, 8, 11, 14 weeks after the first
immunization followed by the measurement. The representative
results are given in fluorescent intensity units (FIU). IgG levels against
peptide 4 and peptide 6, but not any others, became detectable at
3 weeks and reached a maximum at 5 weeks, followed by a decline
thereafter until 11 weeks (*P<0.05; 0 vs. 5 weeks). This analysis was
done using Friedman’s test.
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A dim level of IgG against peptide 8 was detectable at 8
and 11 weeks, but the levels were not significant.
Detection of IgG antibodies in serum of C57BL/6 N (H-2b)
mice
We then measured IgG levels in serum from the vacci-
nated C57BL/6N (H-2b) mice before and 5 weeks after
the immunization to address any difference between
Balb/c and C57BL/6N mice. As a result, IgG against
both peptide 6 and peptide 8, but not any others, were
detected at 5 weeks (P < 0.05) (Figure 2).
Epitope mapping of peptide
These results indicated that peptide 6 is the major com-
mon B cell epitope shared by the two strains. Subse-
quently, epitope mapping of peptide 6 was conducted
with eight different 10-mers (Figure 3). Five amino acids
sequences from the HPV16 L1-derived sequence at pos-
ition 295 to 299 were added to the N-terminal of the
first 10-mer, and those at position 320 to 324 were also
added to the C-terminal of the eighth 10-mer. Each of
these eight peptides shared seven amino acids sequences
with each other. As a result, one 10-mer at amino acid
positions of 304–313 of HPV16 L1, aqifnkpywl, was
determined to be an immunogenic portion using the
antibodies (Figure 3). Then, we addressed the reactivity
of the 9-mer peptide (qifnkpywl) at position 305 to 313,
which had binding motifs to HLA-A2 and HLA-A24, to
immunized sera. A modest level of reactivity to this 9-
mer was observed (Figure 3).Binding capability of the immunogenic B cell epitope to
HLA class I molecules
The identified immunogenic B cell epitope contains
binding motifs to the HLA- A2 and HLA-A24 mole-
cules. Therefore, we examined whether they actually
bind to the HLA-A2- and HLA-A24 molecules by the
HLA class I stabilization assay with TAP-deficient cell
lines RMA-S/A2 and RMA-S/A24. As illustrated in
Table 1, both of the 9-mer (qifnkpywl) and 10-mer
(aqifnkpywl) peptides showed substantial binding cap-
ability to HLA-A2 and HLA-A24.
Discussion
We analyzed immune responses to the 10 different
HPV-VLP L1-derived peptides (20-mers) that had bind-
ing motifs to both HLA-class I (A2 or A24) and HLA-
class II (DR) in animal model. We used BALB/c and
C57BL/6N mice that have been regarded as Th2- and
Th1-skewed strains, respectively, and widely known to
express different immune responses in normal and
pathological states [7]. When we examined humoral im-
mune responses to the 10 different HPV-VLP L1-derived
peptides in the Th2-skewed BALB/c mice, the levels of
IgG to the peptide 4 and peptide 6 were clearly elevated
in the sera after immunization with HPV-VLPs. We also
used the Th1-skewed C57BL/6N mice to examine
whether the selection of mouse strains tested has con-
siderable and variable impacts on humoral immune
responses to HPV-VLPs. In the C57BL/6N mice, one of
the identified peptides , peptide 6 , but not another one
(peptide 4), was also immunogenic, suggesting that the
peptide 6 is a major common B cell epitope peptide in
mice. Notably, our preliminary study has shown that the
peptide 6 is also immunogenic in humans who are vacci-
nated with HPV-VLPs (data not shown), suggesting that
the peptide 6 is a common immunogenic B cell epitope
shared between mice and humans. A dim level of IgG
against peptide 8 was detected in Balb/c mice; thus, pep-
tide 8 might also contain a common epitopic portion.
This issue remains to be studied further.
Mapping analysis of peptide 6 showed 10-mer (aqifnk-
pywl) at positions of 304 to 313 of HPV16 L1 as an im-
munogenic portion. In addition, the 9-mer peptide
(qifnkpywl) at position 305 to 313 with binding motifs to
HLA-A2 and -A24 molecules was also recognized by
immunized sera. It is of note that both these 9-mer and
10-mer peptides showed substantial binding capability to
HLA-A2 and HLA-A24 molecules, the two dominant
HLA-class I A types among Japanese and other ethnics
[8]. The peptide 6 at positions 300 to 319 of HPV16 L1
also contains binding motifs to HLA-class-II DR 1, 3,
and 4 molecules, the dominant molecules expressed in
Japanese and other ethnics [9]. Therefore, the peptide 6
and its fragment might be one of the appropriate
Figure 2 Antibody production in C57BL/6N mice. Serum from C57BL/6N mice was obtained before (n = 9)and 5 weeks after the first
immunization (n = 9), followed by the measurement. Each of fluorescent intensity units (FIU) from the 9 individual mice was shown. IgG against
both peptide 6 and peptide 8, but not any others, was detected at 5 weeks after the immunization. Only the P values that were statistically
significant(P< 0.05)are shown. Wilcoxon rank sum test was used for this analysis.
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responses to HPV-VLP after vaccination both in animal
model and humans. This hypothesis is now under inves-
tigation in humans.
Whether the vaccine-induced IgG to the peptide 6 or
8 possesses biological activity to either neutralize HPV
infection or facilitate the prophylactic effect of the HPV
16/18L1 vaccine needs to be studied in near future. In










Figure 3 Epitope mapping of peptide 6 with eight different 10-mer p
sequence at position 295 to 299 were added to the N-terminal of the first
terminal of the eighth 10-mer (left side of the figure). Each of these eight p
addressed the reactivity to immunized sera of the 9-mer peptide (qifnkpyw
HLA-A24. Representative results are given in the right side of the figure. Th
is shown (*P < 0.05 to any others tested). Wilcoxon rank sum test was usedare often recognized by both B cells and T cells [10], T
cell responses to the peptide 6 and its fragment may also
be of great interest.Conclusions
In summary, one 20-mer peptide at positions 300 to 319
was identified as a common B cell epitope in both Balb/





eptides. Five amino acids sequences from the HPV16 L1-derived
10-mer, and those at position 320 to 324 were added to the C-
eptides shares seven amino acids sequences with each other. We also
l) at positions 305 to 313, which had binding motifs to HLA-A2 and
e highest reactivity to one 10-mer (aqifnkpywl at position 304 to 313)
for this analysis.
Table 1 HLA-binding capability of the B cell epitopse
derived from HPV16 L1
Peptide Sequence Binding capability (%)*
HLA-A2 HLA-A24
9-mer QIFNKPYWL 66.8 40.3
10-mer AQIFNKPYWL 74.9 51.7
Flu M1 GILGFVFTL 116.7 ND
EBV TYGPVFMCL ND 170.6
K-Ras KLVVVG AGGV 3.3 3.8
*HLA-A2 or HLA-A24-binding capability was estimated by increase in mean
fluorescence intensity (MFI), determined by flowcytometry after staining of
RMA-S/A2 or RMA-S/A24 cells with anti-HLA-A2 or anti-HLA-A24 mAb, as
follows; MFI increase (%) = (MFI with a given peptide – MFI without peptide)/
(MFI without peptide) X 100. As positive controls, an HLA-A2-binding peptide
derived from influenza virus M1 (Flu M1) or an HLA-A24-binding peptide
derived from Epstein-Barr virus LMP2 (EBV) was used. As a negative control, a
peptide derived from oncogene K-ras was used. ND, not determined.
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of immune responses to HPV 16L1.Materials and methods
Immunization of mice
Female Balb/c (H-2d) and C57BL/6N (H-2b) mice used
in this study were 6 weeks of age and were maintained
in a pathogen-free environment. Balb/c mice (H-2d)
were mainly provided for the study because they have
been regarded as a Th2- skewed strain [7] and the bind-
ing motifs of the peptides to the H-2d class I-A mole-
cules were similar to those of human leukocyte antigen
(HLA) class I-A2402, which are expressed in 60% of
Japanese [11]. We administered the bivalent HPV-16/18
virus-like particle AS04 vaccine, containing 2 μg each of
HPV-16 and HPV-18L1 VLPs with AS04 adjuvant that
contained 50 μg aluminum hydroxide and 5 μg 3-
deacylated monophosphoryl lipid A. Mice were immu-
nized twice (day 1 and day 21) into the muscle at theTable 2 HPV16 L1-derived peptides used in this study and th
DR A2
position Amino acid sequence position Amino
Peptide 1 54-73 KPNNNKILVPKVSGLQYRVF 60-68 ILVPKV
Peptide 2 392-422 HSMNSTILEDWNFGLQPPPGG 398-406 ILEDW
Peptide 3 62-81 VPKVSGLQYRVFRIHLPDPN 67-75 GLQYR
Peptide 4 112-131 PLGVGISGHPLLNKLDDTEN 118-126 SGHPL
Peptide 5 243-262 GDSLFFYLRREQMFVRHLFN 249-257 YLRREQ
Peptide 6 300-319 VTSDAQIFNKPYWLQRAQGH 305-313 QIFNKP
Peptide 7 144-162 RECISMDYKQTQLCLIGCK 148-156 SMDYK
Peptide 8 293-312 PTPSGSMVTSDAQIFNKPYW 298-306 SMVTS
Peptide 9 384-403 TADVMTYIHSMNSTILEDWN 390-399 YIHSM
Peptide 10 152-171 KQTQLCLIGCKPPIGEHWG 157-165 CLIGCK
Anchor residues for HLA class I are shown in boldface.thigh with HPV16/18 VLP AS04 vaccine based on the
report by Didierlaurent et al. [12].
All experiments with live animals were performed
under the institutional guidelines of the animal experi-
ment in Kurume University after the approval by the
Committee of Animal Experiment in Kurume University
(Approval Number: 2010-107-1).
Collection of serum samples
The blood of each mouse was collected from the orbital
sinus. Blood collection was performed before vaccin-
ation, and 3, 5, 8, 11, and 14 weeks after the first
immunization in Balb/C (n = 6 in each group). In
C57BL/6 mice, blood was collected before (n = 9) and
5 weeks after the first immunization (n = 9). Collected
blood was allowed to coagulate by keeping it at room
temperature for 1 h followed by centrifugation and col-
lection. Serum from each mouse was sealed and stored
at −80°C until use. Measurement of IgG titers was con-
ducted simultaneously to avoid possible in vitro biases.
Peptides
Ten different HPV16 L1-derived peptides (20-mer) with
binding motifs to both HLA-class I (A2 or A24) and
HLA-class II (DR) were selected by the web software
(MULTIPRED) (Table 2). This choice was based on con-
sideration of future applications to the human immune
system. For epitope mapping, 8 different 10-mer and
one 9-mer peptides were selected from the 20-mer pep-
tide 6. These peptides were purchased from Greiner Bio-
One (Thermo Fisher Scientific, Ulm, Germany). Each
peptide was dissolved in dimethyl sulfoxide (DMSO),
stored at −80°C.
Preparation of xMAP beads
The xMAP carboxylate beads and Luminex system plat-
form were obtained from Luminex Corp. (Austin, TX) aseir binding motifs to HLA-A2 and -A24
4A2
acid sequence Score position Amino acid sequence Score
SGL 30 59-68 KILVPKVSGL 14
NFGL 23 397-406 TILEDWNFGL 16
VFRI 22 66-75 SGLQYRVFRI 24
LNKL 22 117-126 ISGHPLLNKL 12
MFV 22 248-257 FYLRREQMFV 12
YWL 21 305-313 QIFNKPYWL 12
QTQL 20 148-156 SMDYKQTQL 11
DAQI 20 298-306 SMVTSDAQI 10
NSTIL 20 389-398 TYIHSMNSTI 23
PPI 23 156-165 LCLIGCKPPI 12
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(MABVN12) and vacuum manifold apparatus (MAVM
09601) were from Millipore Corp. (Bedford, MA). Bioti-
nylated goat anti mouse IgG (gamma chain-specific)
(SouthernBiotech, AL) was purchased from Vector La-
boratories Inc. (Burlingame, CA). Streptavidin-PE (S-
866) was purchased from Molecular Probes (Eugene,
OR). 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide
hydrochloride (EDC, 22980) was obtained from PIERCE
(Rockford, IL). Peptides were coupled to xMAP beads
according to the modified manufacturer’s instructions as
reported previously [13]. In brief, 100 μ of xMAP beads
were washed with 0.1 M MES buffer, pH 7.0, followed
by mixing with 100 μl of peptide (1 mg/ml in 0.1 M
MES buffer, pH 7.0). The peptide-loaded beads were
incubated with EDC (1 mg/ml) at room temperature for
30 min in darkness, and then incubated twice more
under the same conditions, after which the beads were
washed with 0.05% Tween 20-PBS. Finally, the beads
were treated with 2-aminoethanol for 15 min at room
temperature in darkness, then washed twice and re-
suspended with 1 ml of 0.05% NaN3 in Block-Ace.
Anti-peptide antibody measurement by multiplexed
bead-based Luminex assay
Blood samples were obtained from each of the mice at
each scheduled point. Peptide-specific IgG levels in serum
were measured by flowmetry assay using the Luminex
system as reported previously [13]. In brief, serum was
incubated with 100 μl of the peptide-coded beads for
1.5 hours at room temperature in a 96-well filter plate on
a plate shaker. After incubation, the plate was washed
using a vacuum manifold apparatus and incubated with
100 μl of biotinylated goat anti mouse IgG (gamma
chain-specific) for 1 hour at room temperature on a plate
shaker. The plate was then washed, 100 μl of streptavidin-
PE was added to the wells, and the plate was incubated
for 40 min at room temperature on a plate shaker. The
bound beads were washed three times followed by the
addition of 100 μl of Tween 20-PBS into each well, and
the plate was placed for 3 min on a plate shaker.
HLA class I stabilization assay
The actual binding of the peptides to HLA-A2 or HLA-
A24 molecules was evaluated by MHC class I
stabilization assay with the TAP2-deficient RMA-S cells
stably transfected with the HLA-A*0201 gene (RMA-S/
A2) or with the HLA-A*2402/Kb gene (RMA-S/A24),
according to a previously reported method with several
modifications [14]. Briefly, RMA-S/A2 or RMA-S/A24
cells (5x105 cells per well in a 24-well plate) were cul-
tured for 18 hours at 26°C in 1 ml of RPMI 1640
medium (Invitrogen Inc, Carlsbad, CA) containing 10%
FBS (MP Biologicals, Solon, OH) in the presence ofsynthetic peptides (25 μg/ml) and β2-microglobulin
(2 μg/ml; Fitzgerald Industries International, Acton,
MA). After washing, the cells were cultured for 3 hours
at 37°C, and then stained with anti-HLA-A2 mAb
(BB7.2; BD Bioscience, San Jose, CA) or anti-HLA-A24
mAb (One Lambda, Inc. Canoga Park, CA), followed by
incubation with PE-conjugated rabbit anti-mouse IgG
Ab (MP Biomedicals, Solon, OH). After washing, the
cells were suspended with 1 ml of PBS containing 1%
formaldehyde, and analyzed with FACSCanto (BD Bio-
science). The binding capability of each peptide to HLA-
A2 or HLA-A24 molecules was evaluated by the in-
crease in mean fluorescence intensity (MFI) assessed by
flow cytometry, as follows: MFI increase (%) = (MFI with
a given peptide – MFI without peptide)/(MFI without
peptide) X 100. As positive controls, an HLA-A2-
binding peptide derived from influenza virus M1 (Flu
M1, GILGFVFTL) or an HLA-A24-binding peptide
derived from Epstein-Barr virus LMP2 (EBV,
TYGPVFMCL) was used. As a negative control, a pep-
tide derived from oncogene K-ras (KLVVVG AGGV)
was used.Statistics
The statistical significance of the data was determined
using Friedman`s test and the Wilcoxon rank sum test.
P-values less than 0.05 were considered statistically
significant.
Abbreviations
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